Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand.

Sharma M, Ortendahl J, van der Ham E, Sy S, Kim JJ.

BJOG. 2012 Jan;119(2):166-76. doi: 10.1111/j.1471-0528.2011.02974.x. Epub 2011 Apr 12.

3.

[Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].

Westra TA, Daemen T, Postma MJ, Wilschut JC.

Ned Tijdschr Geneeskd. 2009;153:A356. Review. Dutch.

PMID:
19930733
4.

What's next? Perspectives and future needs of cervical screening in Europe in the era of molecular testing and vaccination.

Lynge E, Antilla A, Arbyn M, Segnan N, Ronco G.

Eur J Cancer. 2009 Oct;45(15):2714-21. doi: 10.1016/j.ejca.2009.07.024. Epub 2009 Aug 18. Review.

PMID:
19695870
5.

Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.

Tota J, Mahmud SM, Ferenczy A, Coutlée F, Franco EL.

Sex Health. 2010 Sep;7(3):376-82. doi: 10.1071/SH10022. Review.

PMID:
20719230
6.

Cervical cancer screening in high- and low-resource countries: implications and new developments.

Hoppenot C, Stampler K, Dunton C.

Obstet Gynecol Surv. 2012 Oct;67(10):658-67. doi: 10.1097/OGX.0b013e3182732375. Review.

PMID:
23112073
7.

Integrating human papillomavirus vaccination in cervical cancer control programmes.

Franco EL, Coutlée F, Ferenczy A.

Public Health Genomics. 2009;12(5-6):352-61. doi: 10.1159/000214925. Epub 2009 Aug 11. Review.

PMID:
19684447
8.

The current and future role of screening in the era of HPV vaccination.

Myers E, Huh WK, Wright JD, Smith JS.

Gynecol Oncol. 2008 May;109(2 Suppl):S31-9. doi: 10.1016/j.ygyno.2008.02.001. Review. Erratum in: Gynecol Oncol. 2008 Aug;110(2):270.

PMID:
18482556
9.

Quadrivalent human papillomavirus vaccine.

Barr E, Tamms G.

Clin Infect Dis. 2007 Sep 1;45(5):609-7. Epub 2007 Jul 25. Review.

PMID:
17682997
10.

The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.

Setiawan D, Luttjeboer J, Westra TA, Wilschut JC, Suwantika AA, Daemen T, Atthobari J, Wilffert B, Postma MJ.

Expert Rev Vaccines. 2015 Apr;14(4):589-604. doi: 10.1586/14760584.2014.990386. Epub 2014 Dec 6. Review.

PMID:
25482311
11.

Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review.

Fesenfeld M, Hutubessy R, Jit M.

Vaccine. 2013 Aug 20;31(37):3786-804. doi: 10.1016/j.vaccine.2013.06.060. Epub 2013 Jul 3. Review.

PMID:
23830973
12.

The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.

Holmes J, Hemmett L, Garfield S.

Eur J Health Econ. 2005 Mar;6(1):30-7. Review.

PMID:
15682286
13.

Cervical cancer in the human papillomavirus vaccination era.

Tay SK.

Curr Opin Obstet Gynecol. 2012 Feb;24(1):3-7. doi: 10.1097/GCO.0b013e32834daed9. Review.

PMID:
22123221
14.

Cervical cancer control in India: taking evidence to action.

Farooqui HH, Zodpey S.

J Public Health Policy. 2012 May;33(2):165-72. doi: 10.1057/jphp.2012.7. Review.

PMID:
22555096
15.

Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.

Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA.

Vaccine. 2013 Dec 29;31 Suppl 5:F47-52. doi: 10.1016/j.vaccine.2012.06.066. Review.

PMID:
24331747
16.

Cervical cancer screening at crossroads.

Lynge E, Rygaard C, Baillet MV, Dugué PA, Sander BB, Bonde J, Rebolj M.

APMIS. 2014 Aug;122(8):667-73. doi: 10.1111/apm.12279. Review.

PMID:
25046198
17.

[Developments in HPV vaccination].

de Melker H, Kenter G, van Rossum T, Conyn-van Spaendonck M.

Ned Tijdschr Geneeskd. 2012;156(47):A5410. Review. Dutch.

PMID:
23171565
18.

Global strategies for cervical cancer prevention.

Pimple S, Mishra G, Shastri S.

Curr Opin Obstet Gynecol. 2016 Feb;28(1):4-10. doi: 10.1097/GCO.0000000000000241. Review.

PMID:
26642063
19.

Human papillomavirus as a target for management, prevention and therapy.

Crosbie EJ, Kitchener HC.

Int J Hyperthermia. 2012;28(6):478-88. doi: 10.3109/02656736.2012.677934. Epub 2012 Jun 12. Review.

PMID:
22690976
20.

Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations.

Ekwunife OI, O'Mahony JF, Gerber Grote A, Mosch C, Paeck T, Lhachimi SK.

Pharmacoeconomics. 2017 Jan;35(1):65-82. doi: 10.1007/s40273-016-0451-7. Review.

Supplemental Content

Support Center